Time abides long enough for those who make use of it

Table 1 Time to treatment initiation (TTI) Evaluations

	Data Source	Years	n	Site	Median TTI	HR^a
Fortin A [25]	Retrospective single institution	1988–1997	623	T1-2 N0 HNC	1989: 28 d	1.45 (1.06–1.97)
				55% Larynx	1995: 46 d	Delay > 30 d
					1997: 55 d	Delay > 30 d
Leon X [23]	Retrospective single institution	1985–1998	797	All HNC	44 d	0.99 (0.83–1.19)
Leon X [23]	Retrospective single institution	1985–1998	797	45% Larynx	44 d	Delay > 33 d
Hansen O [13]	Retrospective single institution	1965–1997	611	Stage I-III	21 d	1.16 (0.84–1.59)
Hansen O [13]	Retrospective single institution	1965–1997	611	Glottic Cancer	21 d	Continuous
Caudell J [24]	Retrospective single institution	1995–2007	427	Stage III-IV HNC	34 d	1.002 (0.999–1.005)
Caudell J [24]	Retrospective single institution	1995–2007	427	55% Oropharynx	34 d	Continuous
Liang H [22]	Retrospective single institution	1998–2013	9896	Stage I-IV NPC	RT: 20 d	1.13 (1.04–1.23)
Liang H [22]	Retrospective single institution	1998–2013	9896	45% Stage III	CRT: 22 d	Delay > 30 d
Murphy CT [26]	Prospective Database	2003–2006	51,655	All HNC	26 d	1.08 (1.03–1.13)
Murphy CT [26]	Prospective Database	2003–2006	51,655	42% Larynx	26 d	Delay 61–90 d

HNC = head and neck cancer, RT = RT alone, CRT = chemoradiation, d = days
^aHR is a comparison of survival as a function of increased TTI. Comparison is TTI ≤ 30 days v the interval specified or an evaluation of increased TTI as a continuous variable

ISSN: 2059-7347